Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The price of Monte Rosa Therapeutics Inc (NASDAQ: GLUE) closed at $22.84 in the last session, down -0.78% from day before closing price of $23.02. In other words, the price has decreased by -$0.78 from its previous closing price. On the day, 1.05 million shares were traded. GLUE stock price reached its highest trading level at $23.9489 during the session, while it also had its lowest trading level at $22.76.
Ratios:
We take a closer look at GLUE’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.45 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.01. For the most recent quarter (mrq), Quick Ratio is recorded 6.54 and its Current Ratio is at 6.54. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.15.
Upgrades & Downgrades
In the most recent recommendation for the company, Wells Fargo on December 19, 2024, Downgraded its rating to Equal Weight and sets its target price to $11 from $14 previously.
On February 15, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $11.
Wells Fargo Upgraded its Equal Weight to Overweight on January 03, 2023, while the target price for the stock was maintained at $18.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 07 ’26 when Warmuth Markus sold 5,466 shares for $23.49 per share. The transaction valued at 128,373 led to the insider holds 618,937 shares of the business.
Warmuth Markus bought 5,466 shares of GLUE for $128,372 on Jan 07 ’26. On Jan 05 ’26, another insider, Nickson Philip, who serves as the Chief Business & Legal Officer of the company, sold 3,155 shares for $15.17 each. As a result, the insider received 47,861 and left with 60,845 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GLUE now has a Market Capitalization of 1741384704 and an Enterprise Value of 1136199680. As of this moment, Monte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 74.79. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.59 while its Price-to-Book (P/B) ratio in mrq is 5.74. Its current Enterprise Value per Revenue stands at 6.259 whereas that against EBITDA is 67.47.
Stock Price History:
The Beta on a monthly basis for GLUE is 1.61, which has changed by 2.972174 over the last 52 weeks, in comparison to a change of 0.15024745 over the same period for the S&P500. Over the past 52 weeks, GLUE has reached a high of $25.77, while it has fallen to a 52-week low of $3.50. The 50-Day Moving Average of the stock is 28.41%, while the 200-Day Moving Average is calculated to be 155.22%.
Shares Statistics:
According to the various share statistics, GLUE traded on average about 1.60M shares per day over the past 3-months and 1851130 shares per day over the past 10 days. A total of 61.79M shares are outstanding, with a floating share count of 47.71M. Insiders hold about 28.25% of the company’s shares, while institutions hold 60.65% stake in the company. Shares short for GLUE as of 1767139200 were 8454052 with a Short Ratio of 5.28, compared to 1764288000 on 7006369. Therefore, it implies a Short% of Shares Outstanding of 8454052 and a Short% of Float of 16.91.
Earnings Estimates
The market rating of Monte Rosa Therapeutics Inc (GLUE) is currently shaped by the ongoing analysis conducted by 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.32 and low estimates of -$0.59.
Analysts are recommending an EPS of between $0.04 and -$0.45 for the fiscal current year, implying an average EPS of -$0.21. EPS for the following year is -$1.38, with 7.0 analysts recommending between $0.25 and -$2.57.
Revenue Estimates
A total of 7 analysts have provided revenue estimates for GLUE’s current fiscal year. The highest revenue estimate was $160.9M, while the lowest revenue estimate was $121M, resulting in an average revenue estimate of $136.47M. In the same quarter a year ago, actual revenue was $75.62M
